Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis BS50
- Development stage
- Unknown
- Lead developer
- BIO-CAT Microbials
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis BS50 is a proprietary, spore-forming probiotic strain developed by BIO-CAT Microbials. Characterized by its robust heat resistance and pH tolerance, the strain is designed to survive the acidic environment of the human stomach to reach the intestines. BS50 has been shown to secrete digestive enzymes and microbiota-modulating molecules that support gastrointestinal function. In clinical studies, daily supplementation with 2x10⁹ CFU of BS50 significantly improved gas-related symptoms, including abdominal bloating, flatulence, and burping, in healthy adults. Preclinical genomic analysis has confirmed the safety profile of the strain, demonstrating an absence of known Bacillus toxins and virulence factors.
- Other names
- Bacillus subtilis BS50
02
Targets
LCT (Lactase-phlorizin hydrolase)
Beyond the preview
Go deeper on bacillus subtilis BS50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis BS50.